Thiogenesis Therapeutics, Corp. (OTCQX: TTIPF) is a clinical-stage biopharmaceutical company developing sulfur-containing and thiol-based prodrugs for serious pediatric and inherited diseases, particularly rare mitochondrial and metabolic disorders. The Thiogenesis news stream highlights how its lead candidate, TTI-0102, progresses through clinical development and regulatory interactions.
News releases from the company focus heavily on clinical milestones for TTI-0102. These include updates on its randomized, double-blind, placebo-controlled Phase 2 trial in Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like Episodes (MELAS) in Europe, interim analyses describing biomarker activity and biological proof-of-concept, and activation of additional European trial sites. Thiogenesis also reports on plans and regulatory clearances for a Phase 2a trial in Leigh syndrome spectrum in the United States, as well as preparations for a Phase 3 pivotal trial in nephropathic cystinosis and a Phase 2 or Phase 2a trial in pediatric Metabolic Dysfunction-Associated Steatohepatitis (MASH).
Investors and observers can use the TTIPF news page to follow announcements about scientific presentations at mitochondrial disease conferences, late-breaking abstract acceptances, and participation in webinars and panel discussions organized by patient advocacy and research organizations. Corporate updates such as private placements, stock option grants, investor relations agreements, and patent developments related to asymmetric disulfide prodrugs of cysteamine are also reflected in the news flow.
By reviewing Thiogenesis Therapeutics news, readers gain insight into the timing and design of its clinical trials, the company’s focus on mitochondrial oxidative stress and thiol biology, and the regulatory guidance it receives in key jurisdictions. The news page can be revisited regularly to see how the TTIPF development pipeline and corporate strategy evolve over time based on company disclosures.
Thiogenesis Therapeutics (OTCQX: TTIPF) plans a Phase 3 pivotal clinical trial of lead candidate TTI-0102 for nephropathic cystinosis. The company said TTI-0102 is designed to improve tolerability and simplify dosing versus existing therapies. Thiogenesis intends to submit an Investigational New Drug (IND) application in early 2026 to support initiation of the pivotal study. TTI-0102 is part of a pipeline of next-generation sulfur-based prodrugs for rare mitochondrial and metabolic diseases.
Thiogenesis (OTCQX: TTIPF) reported positive blinded interim Phase 2 results for TTI-0102 in MELAS on November 4, 2025. The analysis covers nine patients (six active, three placebo) and shows biological proof-of-concept, dose discovery and biomarker improvements with clear differentiation among active patients.
Four patients under 50 kg discontinued for dose-dependent side effects, prompting planned dual dosing regimens for different weight cohorts. Final 6-month Radboud data are expected by January 2026 and an IMPD filing to enable a pivotal Phase 3 in Europe is planned for 2026. FDA accepted an IND for Leigh syndrome and a planned IND for nephropathic cystinosis targets a Phase 3 non-inferiority trial.
Thiogenesis Therapeutics (TSXV: TTI; OTC: TTIPF) announced on October 3, 2025 a 3-month extension of its investor relations agreement with Triomphe Holdings Ltd. (Capital Analytica) through December 31, 2025. The Consultant will be paid $5,000 per month for a total cash consideration of $15,000. No securities will be issued in connection with the extension and all other original agreement terms remain unchanged. Services include social media consultation, social sentiment and engagement reporting, forum monitoring, corporate video dissemination and related investor relations services. The Company and Consultant are arm's length, the Consultant holds no present interest in the Company or its securities, and the extension is subject to acceptance by the TSX Venture Exchange.
Thiogenesis Therapeutics (OTCQX:TTIPF), a clinical-stage biopharmaceutical company, held its Annual General Meeting and provided significant corporate updates. The company successfully raised C$4.15 million through an oversubscribed private placement in August 2025.
Key developments include FDA clearance for TTI-0102's IND application in Leigh Syndrome Spectrum, EMA scientific advice for pediatric MASH trial, and progress in the Phase 2 MELAS trial with first two patients dosed. An interim analysis of the MELAS trial is expected in October 2025.
The company reappointed its board members and granted 150,000 stock options to two directors, exercisable at $0.75 per share.
Thiogenesis Therapeutics (OTCQX: TTIPF) received positive guidance from the EMA's CHMP supporting their IMPD submission for a Phase 2a clinical trial of TTI-0102 in pediatric MASH patients. The trial will evaluate the company's third-generation disulfide prodrug of cysteamine in children aged 10-17 with biopsy-confirmed MASH.
The open-label, single-arm trial will assess safety, tolerability, pharmacokinetics, and pharmacodynamic effects, focusing on changes in liver enzymes and mitochondrial biomarkers. Additionally, Thiogenesis secured a crucial European Union patent for its asymmetric disulfide prodrugs of cysteamine, extending protection until 2038.
Thiogenesis Therapeutics (OTCQX: TTIPF) has initiated its Phase 2 clinical trial for TTI-0102, its lead product candidate targeting MELAS (Mitochondrial Encephalomyopathy with Lactic Acidosis and Stroke-like Episodes). The first two patients were dosed on May 12th at Radboud University Medical Center in Netherlands.
The multi-center trial will be conducted in the Netherlands and France, enrolling 12 patients total (8 receiving TTI-0102, 4 receiving placebo) in a randomized, double-blind, placebo-controlled study over 6 months. Key clinical endpoints include the 12-Minute Walking Test, Fatigue Severity Scale, and Quality of Life Assessment, with an interim analysis planned at 3 months.
TTI-0102 is designed to increase intracellular antioxidant glutathione and amino acid taurine, both deficient in MELAS patients. Currently, there are no approved drugs for MELAS in the EU or U.S.